Meet Moderna's Most Likely Blockbusters After Its COVID Vaccine

Prior to the onset of the COVID-19 pandemic, the Moderna candidate that typically received the most attention was its hopeful cytomegalovirus (CMV) vaccine, mRNA-1647. CMV ranks as the leading cause of birth defects in the U.S. Up to 12% of babies with symptomatic CMV die before they're 1 year old. At least 70% of those who survive will experience disabilities. And there's currently no approved CMV vaccine.